These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 36187401)

  • 41. PD-1/PD-L1 Immuno-Mediated Therapy in NAFLD: Advantages and Obstacles in the Treatment of Advanced Disease.
    Lombardi R; Piciotti R; Dongiovanni P; Meroni M; Fargion S; Fracanzani AL
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269846
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.
    Younossi ZM; Otgonsuren M; Henry L; Venkatesan C; Mishra A; Erario M; Hunt S
    Hepatology; 2015 Dec; 62(6):1723-30. PubMed ID: 26274335
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Magnitude of Nonalcoholic Fatty Liver Disease: Eastern Perspective.
    Ching-Yeung Yu B; Kwok D; Wong VW
    J Clin Exp Hepatol; 2019; 9(4):491-496. PubMed ID: 31516265
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Viral Status and Efficacy of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review With Meta-Analysis.
    Ding Z; Dong Z; Chen Z; Hong J; Yan L; Li H; Yao S; Yan Y; Yang Y; Yang C; Li T
    Front Immunol; 2021; 12():733530. PubMed ID: 34659220
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gut microbiome in HCC - Mechanisms, diagnosis and therapy.
    Schwabe RF; Greten TF
    J Hepatol; 2020 Feb; 72(2):230-238. PubMed ID: 31954488
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: from bedside to bench and back.
    Yilmaz Y; Colak Y; Kurt R; Senates E; Eren F
    Tumori; 2013; 99(1):10-6. PubMed ID: 23548993
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
    Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
    Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
    Rizzo A; Cusmai A; Gadaleta-Caldarola G; Palmiotti G
    Expert Rev Gastroenterol Hepatol; 2022 Apr; 16(4):333-339. PubMed ID: 35403533
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma.
    Li R; Zhao W; Liang R; Jin C; Xiong H
    Front Mol Biosci; 2022; 9():917839. PubMed ID: 35847972
    [No Abstract]   [Full Text] [Related]  

  • 51. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
    Oura K; Morishita A; Tani J; Masaki T
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey.
    Tokushige K; Hyogo H; Nakajima T; Ono M; Kawaguchi T; Honda K; Eguchi Y; Nozaki Y; Kawanaka M; Tanaka S; Imajo K; Sumida Y; Kamada Y; Fujii H; Suzuki Y; Kogiso T; Karino Y; Munekage K; Kuromatsu R; Oeda S; Yanase M; Mori K; Ogawa Y; Seko Y; Takehara T; Itoh Y; Nakajima A; Kanemasa K; Nishino K; Masaki N; Takahashi H; Seike M; Torimura T; Saibara T; Toyota J; Chayama K; Hashimoto E
    J Gastroenterol; 2016 Jun; 51(6):586-96. PubMed ID: 26456168
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of Exosomes in Immunotherapy of Hepatocellular Carcinoma.
    Tian BW; Han CL; Dong ZR; Tan SY; Wang DX; Li T
    Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36011030
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of immune tolerance mechanisms on the efficacy of immunotherapy in primary and secondary liver cancers.
    Sankar K; Pearson AN; Worlikar T; Perricone MD; Holcomb EA; Mendiratta-Lala M; Xu Z; Bhowmick N; Green MD
    Transl Gastroenterol Hepatol; 2023; 8():29. PubMed ID: 37601739
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy.
    Fasano R; Shadbad MA; Brunetti O; Argentiero A; Calabrese A; Nardulli P; Calbi R; Baradaran B; Silvestris N
    Life (Basel); 2021 Dec; 11(12):. PubMed ID: 34947886
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
    Bertot LC; Adams LA
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
    Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
    World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors.
    Dongiovanni P; Romeo S; Valenti L
    World J Gastroenterol; 2014 Sep; 20(36):12945-55. PubMed ID: 25278690
    [TBL] [Abstract][Full Text] [Related]  

  • 59. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
    Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
    Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
    Oda K; Uto H; Mawatari S; Ido A
    Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.